A Phase II Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's Disease

Next Previous
Trial Profile

A Phase II Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's Disease

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2014

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Extramammary Paget disease
  • Focus Therapeutic Use

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 13 Jun 2014 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 31 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top